Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07204275 · ClinicalTrials.gov registry record · Phase 2
A Study to Evaluate Efficacy, Safety, and Tolerability of Povetacicept in Participants With Primary Membranous Nephropathy (pMN)
A Phase 2 study of Primary Membranous Nephropathy, sponsored by Vertex Pharmaceuticals Incorporated.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 176
- Enrollment target
- 20
- Study locations
NCT07204275: Recruiting Phase 2 study of Primary Membranous Nephropathy, sponsored by Vertex Pharmaceuticals Incorporated.
NCT07204275 is a Phase 2 study of Primary Membranous Nephropathy that is actively recruiting participants, run by Vertex Pharmaceuticals Incorporated. The registered enrollment target is 176 participants, above the 114-participant average among 8 other Primary Membranous Nephropathy trials with a reported enrollment target (54% higher). The trial reports 20 study locations across 12 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07204275, a Phase 2 study of Primary Membranous Nephropathy, is actively recruiting participants, sponsored by Vertex Pharmaceuticals Incorporated.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 176 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to evaluate the efficacy, safety, and tolerability of povetacicept in participants with primary membranous nephropathy (pMN).
Conditions Studied
Interventions
- DRUG Tacrolimus
- DRUG Povetacicept
Study Locations (20)
Texas
- El Paso Kidney Specialists - El Paso
- Provecta Research Network - Houston
- DaVita Clinical Research Houston - Houston
- Davita Clinical Research San Antonio - San Antonio
Florida
- Bioresearch Partner - Miami
- CTR Oakwater, LLC - Orlando
- Clinical Site Partners, LLC - Orlando - Winter Park
California
- Academic Medical Research Institute (AMRI) - Los Angeles
- Valiance Clinical Research - Internal Medicine - Tarzana
Georgia
- DaVita Clinical Research Columbus - Columbus
- Georgia Nephrology - Lawrenceville
South Carolina
- Carolina Nephrology Greenville - Greenville
- Carolina Nephrology, PA - Spartanburg
Alabama
- Renal Associates - Montgomery
Arizona
- Southwest Kidney Institute, PLC (SKI) - Surprise - Surprise
Colorado
- Western Nephrology & Metabolic Bone Disease PC - Arvada
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 176 participants |
| Start Date | 2025-09-30 |
| Est. Completion | 2028-12-29 |
| Phase | Phase 2 |
What NCT07204275 shows while recruiting
NCT07204275 is an interventional study that assigns participants to a tested intervention. The registered 176 participants enrollment target is mid-sized for trials with a published cap, above the 114-participant average among 8 other Primary Membranous Nephropathy trials with a reported enrollment target (54% higher).
The record links to 1 condition, with Primary Membranous Nephropathy appearing as the primary indexed condition, and to 2 interventions - of which Tacrolimus is the first listed.
NCT07204275 names 20 study sites across 12 states, led by Texas, Florida, California.
Frequently Asked Questions
What is clinical trial NCT07204275 about?
NCT07204275 is a clinical study titled "A Study to Evaluate Efficacy, Safety, and Tolerability of Povetacicept in Participants With Primary Membranous Nephropathy (pMN)". The purpose of this study is to evaluate the efficacy, safety, and tolerability of povetacicept in participants with primary membranous nephropathy (pMN).
What is the current status of trial NCT07204275?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 176 participants. The study started on 2025-09-30. Estimated completion is 2028-12-29.
What conditions does trial NCT07204275 study?
This clinical trial studies the following conditions: Primary Membranous Nephropathy.
What interventions are being tested in trial NCT07204275?
The interventions under investigation include: Tacrolimus (DRUG), Povetacicept (DRUG).
Who is sponsoring clinical trial NCT07204275?
This trial is sponsored by Vertex Pharmaceuticals Incorporated, which has 191 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07204275 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Colorado, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Primary Membranous Nephropathy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07204275's enrollment target sits among peer trials
176 3rd of 8 higher than 6 of 8 other Primary Membranous Nephropathy trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Primary Membranous Nephropathy trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Study of WAL0921 in Patients With Glomerular Kidney Diseases
RECRUITING · Phase 2
-
A Phase 2 Study of Budoprutug in Subjects With Primary Membranous Nephropathy
RECRUITING · Phase 2
-
Study of ALXN1920 in Adult Participants With Primary Membranous Nephropathy (PMN)
RECRUITING · Phase 2
-
A Study to Examine the Efficacy and Safety of Zanubrutinib Given to Adults With Primary Membranous Nephropathy
ACTIVE NOT RECRUITING · Phase 2
-
A Study to Learn More About the Effects and Safety of Felzartamab Infusions in Adults With Primary Membranous Nephropathy (PMN)
RECRUITING · Phase 3
-
A Study of SNP-ACTH (1-39) Gel in Patients With Primary Membranous Nephropathy
RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03304821 · 176 participants · Phase 2
Granulocyte-Macrophage Stimulating Factor (GM-CSF) in Peripheral Arterial Disease
- NCT03447938 · 176 participants · NA
The Minimally Invasive Coronary Surgery Compared to STernotomy Coronary Artery Bypass Grafting Trial
- NCT03824145 · 176 participants · NA
Every Day Counts: A Lifestyle Program for Women With Metastatic Breast Cancer
- NCT04177914 · 176 participants · Phase 3
HCRN Endoscopic Versus Shunt Treatment of Hydrocephalus in Infants
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI